STEREOTACTIC RADIOTHERAPY FOR THE TREATMENT OF ACOUSTIC NEUROMAS
Clinical White Paper

Acoustic neuromas (AN) have an annual incidence of approximately one per 100,000 people and may account for up to 8% of all new tumors presenting to a neurosurgical referral practice. Acoustic neuromas are benign tumors arising from Schwann cells from the vestibular branch of the eighth cranial nerve. Nevertheless, they can pursue a potentially aggressive course, with uncontrolled local growth resulting in compression of the brainstem and fourth ventricle, cranial nerve and other neurological deficits.

Figure: Details of a typical acoustic neuroma treatment plan

Acoustic neuroma growth rates are variable and inconsistent. An observational wait-and-see approach advocated by many authors, if patients follow up with regular MRI scans and clinical review, can be maintained.

Surgical excision has been the standard treatment for AN, should this become necessary. In recent years, an increasing number of clinical publications regarding stereotactic radiosurgery (SRS) and stereotactic radiotherapy (SRT) have established these techniques as a safe, efficient and minimally invasive alternative.

Furthermore, stereotactic irradiation has gained increased acceptance with the publication of long-term follow up data suggesting high rates of long-term control. SRS is being used increasingly on younger patients. Concern over the additional surgical risks, should progressive tumor growth occur after SRS, remains a controversial but legitimate issue, although descriptions of salvage stereotactic irradiation, as an alternative strategy, are described.

While microsurgery and SRS/SRT achieve similar success rates, no randomized controlled trial exists to guide management. Surgical removal of AN, even with experienced surgeons and modern microsurgical techniques, may be associated with morbidity, including loss of useful hearing, temporary or permanent facial and trigeminal nerve dysfunction.

Combined approaches may be useful for larger tumors to reduce morbidity, as well as the risk of recurrence. Therefore, in the case of a large tumor resulting in brainstem compression and progressive neurological signs, a combined strategy of microsurgical resection followed by SRS or SRT can often be very helpful and the treatment of choice to preserve cranial nerve function and limit the recurrence rate.

For both microsurgery and SRS, the risks of facial, trigeminal and auditory dysfunction are proportional to the size of the treated AN. Cochlear dose also appears a significant factor in hearing preservation after SRS/SRT. SRT results suggest that some cranial nerve dysfunction may be avoided, even with larger tumors.

SRT of an AN is typically performed with a dedicated linear accelerator equipped with a micro-multi-leaf collimator, which improves dose conformity over conical collimators. When comparing treatment details, the dynamic arc technique showed a statistically significant increase in the minimum dose to the target and a better conformity index over fixed fields.

A summary table of some important recent results concerning the SRT treatment of an AN is presented below. In these studies, results are described in terms of local control and hearing preservation.
While local control rates may be overestimated for small tumors, many of the series listed, describe AN with dimensions greater than 18 mm. Here, tumors have been shown to have enhanced proliferative activity, suggesting a meaningful response to SRT treatment.

Hearing preservation was typically determined using the Gardner-Robertson hearing classification scheme. Useful or serviceable hearing was defined as Gardner-Robertson Class I or II after treatment.

Sometimes useful hearing was subjectively defined as the unaided ability to discriminate normal speech and use a telephone with the affected ear.

From the recent literature, it can be concluded that SRT, using advanced imaging and highly conformal field shaping, achieves high rates of tumor control and preservation of useful hearing from 57 to 93%. Because this minimally invasive technique produces only low rates of damage to the facial and trigeminal nerves, SRT can be considered a low-risk and highly effective treatment option.

### Overview of the recent clinical literature on SRT for acoustic neuromas

<table>
<thead>
<tr>
<th>Author</th>
<th>Institution</th>
<th>Year</th>
<th>Patients</th>
<th>Tumor Diameter (mm)</th>
<th>Dose (Gy)</th>
<th># Fractions</th>
<th>% IDL Covering PTV</th>
<th>% Local Control</th>
<th>% Hearing Preservation</th>
<th>% Nerve Toxicity Facial</th>
</tr>
</thead>
<tbody>
<tr>
<td>Williams⁸</td>
<td>John Hopkins University, Baltimore</td>
<td>2002</td>
<td>125</td>
<td>20</td>
<td>25</td>
<td>5</td>
<td>80</td>
<td>100</td>
<td>64 at 2 years</td>
<td>0 / 0</td>
</tr>
<tr>
<td>Meijer⁵</td>
<td>VU Medical Center, Amsterdam</td>
<td>2003</td>
<td>80</td>
<td>25</td>
<td>20 - 25</td>
<td>5</td>
<td>80</td>
<td>94</td>
<td>61 at 5 years</td>
<td>2 / 3</td>
</tr>
<tr>
<td>Selch⁸</td>
<td>David Geffen School of Medicine, Los Angeles</td>
<td>2004</td>
<td>48</td>
<td>22</td>
<td>54</td>
<td>30</td>
<td>90</td>
<td>100</td>
<td>93 at 3 years</td>
<td>2 / 2</td>
</tr>
<tr>
<td>Chung¹⁰</td>
<td>BC Cancer Agency, Vancouver</td>
<td>2004</td>
<td>27</td>
<td>16</td>
<td>45</td>
<td>25</td>
<td>90</td>
<td>100</td>
<td>57 at 2 years</td>
<td>7 / 4</td>
</tr>
<tr>
<td>Combs⁸</td>
<td>University of Heidelberg</td>
<td>2010</td>
<td>172</td>
<td>N/A</td>
<td>58</td>
<td>32</td>
<td>90</td>
<td>96</td>
<td>78 at 5 years</td>
<td>3 / 2</td>
</tr>
<tr>
<td>Meijer⁷</td>
<td>VU Medical Center, Amsterdam</td>
<td>2008</td>
<td>20</td>
<td>25</td>
<td>20 - 25</td>
<td>5</td>
<td>80</td>
<td>100</td>
<td>N/A</td>
<td>0 / 0</td>
</tr>
<tr>
<td>Andrews¹¹</td>
<td>Thomas Jefferson University, Philadelphia</td>
<td>2009</td>
<td>46</td>
<td>N/A</td>
<td>46.8</td>
<td>26</td>
<td>90</td>
<td>100</td>
<td>79 at 3 years</td>
<td>0 / 0</td>
</tr>
</tbody>
</table>

References:

[16] Iwai Y. et al., Neurosurg 60, ONS75, 2007
[17] Yomo S. et al., Neurosurg 64, 48, 2009